Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine

Kah Whye Peng; Timothy Carey; Patrycja Lech; Rianna Vandergaast; Miguel Muñoz-Alía; Nandakumar Packiriswamy; Clement Gnanadurai; Karina Krotova; Mulu Tesfay; Christopher Ziegler; Michelle Haselton; Kara Sevola; Chase Lathrum; Samantha Reiter; Riya Narjari; Baskar Balakrishnan; Lukkana Suksanpaisan; Toshie Sakuma; Jordan Recker; Lianwen Zhang; Scott Waniger; Luke Russell; Christopher D. Petro; Christos A. Kyratsous; Alina Baum; Jody L. Janecek; Rachael M. Lee; Sabarinathan Ramachandran; Melanie L. Graham; Stephen J. Russell

doi:10.1016/j.vaccine.2021.12.063

Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine

Kah Whye Peng, Timothy Carey, Patrycja Lech, Rianna Vandergaast, Miguel Muñoz-Alía, Nandakumar Packiriswamy, Clement Gnanadurai, Karina Krotova, Mulu Tesfay, Christopher Ziegler, Michelle Haselton, Kara Sevola, Chase Lathrum, Samantha Reiter, Riya Narjari, Baskar Balakrishnan, Lukkana Suksanpaisan, Toshie Sakuma, Jordan Recker, Lianwen ZhangScott Waniger, Luke Russell, Christopher D. Petro, Christos A. Kyratsous, Alina Baum, Jody L. Janecek, Rachael M. Lee, Sabarinathan Ramachandran, Melanie L. Graham, Stephen J. Russell

Molecular Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.

Original language	English (US)
Pages (from-to)	2342-2351
Number of pages	10
Journal	Vaccine
Volume	40
Issue number	15
DOIs	https://doi.org/10.1016/j.vaccine.2021.12.063
State	Published - Apr 1 2022

Keywords

Neutralizing antibodies
Oral vaccine
Rhabdovirus
SARS-CoV-2
T cells
VSV

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2021.12.063

Cite this

Peng, K. W., Carey, T., Lech, P., Vandergaast, R., Muñoz-Alía, M., Packiriswamy, N., Gnanadurai, C., Krotova, K., Tesfay, M., Ziegler, C., Haselton, M., Sevola, K., Lathrum, C., Reiter, S., Narjari, R., Balakrishnan, B., Suksanpaisan, L., Sakuma, T., Recker, J., ... Russell, S. J. (2022). Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine. Vaccine, 40(15), 2342-2351. https://doi.org/10.1016/j.vaccine.2021.12.063

Peng, KW, Carey, T, Lech, P, Vandergaast, R, Muñoz-Alía, M, Packiriswamy, N, Gnanadurai, C, Krotova, K, Tesfay, M, Ziegler, C, Haselton, M, Sevola, K, Lathrum, C, Reiter, S, Narjari, R, Balakrishnan, B, Suksanpaisan, L, Sakuma, T, Recker, J, Zhang, L, Waniger, S, Russell, L, Petro, CD, Kyratsous, CA, Baum, A, Janecek, JL, Lee, RM, Ramachandran, S, Graham, ML & Russell, SJ 2022, 'Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine', Vaccine, vol. 40, no. 15, pp. 2342-2351. https://doi.org/10.1016/j.vaccine.2021.12.063

@article{d95e6255c91449f496873ed8801bd2fe,

title = "Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine",

abstract = "An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.",

keywords = "Neutralizing antibodies, Oral vaccine, Rhabdovirus, SARS-CoV-2, T cells, VSV",

author = "Peng, {Kah Whye} and Timothy Carey and Patrycja Lech and Rianna Vandergaast and Miguel Mu{\~n}oz-Al{\'i}a and Nandakumar Packiriswamy and Clement Gnanadurai and Karina Krotova and Mulu Tesfay and Christopher Ziegler and Michelle Haselton and Kara Sevola and Chase Lathrum and Samantha Reiter and Riya Narjari and Baskar Balakrishnan and Lukkana Suksanpaisan and Toshie Sakuma and Jordan Recker and Lianwen Zhang and Scott Waniger and Luke Russell and Petro, {Christopher D.} and Kyratsous, {Christos A.} and Alina Baum and Janecek, {Jody L.} and Lee, {Rachael M.} and Sabarinathan Ramachandran and Graham, {Melanie L.} and Russell, {Stephen J.}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2022",

month = apr,

day = "1",

doi = "10.1016/j.vaccine.2021.12.063",

language = "English (US)",

volume = "40",

pages = "2342--2351",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "15",

}

TY - JOUR

T1 - Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine

AU - Peng, Kah Whye

AU - Carey, Timothy

AU - Lech, Patrycja

AU - Vandergaast, Rianna

AU - Muñoz-Alía, Miguel

AU - Packiriswamy, Nandakumar

AU - Gnanadurai, Clement

AU - Krotova, Karina

AU - Tesfay, Mulu

AU - Ziegler, Christopher

AU - Haselton, Michelle

AU - Sevola, Kara

AU - Lathrum, Chase

AU - Reiter, Samantha

AU - Narjari, Riya

AU - Balakrishnan, Baskar

AU - Suksanpaisan, Lukkana

AU - Sakuma, Toshie

AU - Recker, Jordan

AU - Zhang, Lianwen

AU - Waniger, Scott

AU - Russell, Luke

AU - Petro, Christopher D.

AU - Kyratsous, Christos A.

AU - Baum, Alina

AU - Janecek, Jody L.

AU - Lee, Rachael M.

AU - Ramachandran, Sabarinathan

AU - Graham, Melanie L.

AU - Russell, Stephen J.

PY - 2022/4/1

Y1 - 2022/4/1

N2 - An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.

AB - An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.

KW - Neutralizing antibodies

KW - Oral vaccine

KW - Rhabdovirus

KW - SARS-CoV-2

KW - T cells

KW - VSV

UR - http://www.scopus.com/inward/record.url?scp=85126104088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126104088&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2021.12.063

DO - 10.1016/j.vaccine.2021.12.063

M3 - Article

C2 - 35282925

AN - SCOPUS:85126104088

SN - 0264-410X

VL - 40

SP - 2342

EP - 2351

JO - Vaccine

JF - Vaccine

IS - 15

ER -

Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this